Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study. Tislelizumab in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results